Treatment Therapies in Renal Cell Carcinoma in elderly: A Descriptive Analysis
Abstract
Kidney cancer accounts for 63% of cancers that affect the elderly and access to innovative therapies are needed to diagnose and treatment. So this study was conducted with the aim to find out the type of better therapy in renal cancer in elderly. This study was conducted on 21 cases of renal cell cancer in first group and 64 cases in group II . Use of humanized monoclonal antibodies administered at a dose of 10 mg / kg in combination with the alpha allIFN 9 (MUI) dose subcutaneously three times a week for three months with a positive response at 12 months in 91% of cases. AC of the kidney is a typical disease of geriatric and the prognosis is greatly influenced by other underlying conditions, surgery is the treatment of choice healing while finding difficulty in implementing patient with: renal insufficiency, solitary kidney, or in 30% of cases (occasional) in late-stage cancers. the chemotherapy used in association to IFN led to a partial response in the progression of the disease 15% of cases. Results show that in these cases treated with this therapy had encouraging results in terms of complete response, partial response and stable disease. Disappointing results reported (chemo, radio,) in this study have led to the use of biological response modifiers establishing itself as the treatment of choice (first results) in advanced kidney cancer, in combination with lIFN 2alfa. Additional molecular biology studies are useful for better understanding of the mechanisms that regulate the aging process and the onset of illness in old age.
Keywords
Download Options
Introduction
About half of new diagnoses of renal cell carcinoma, is placed in patients over 65 years, in particular in a 25% of cases between 65 and 74 years and in another 25% of cases over 75 years. 1,2,3 Age is a risk factor for neoplastic disease. The causes are to be found in the immunological modification, failure to early diagnosis, poor screening sensitivity, to functional decline and the progressive isolation. the tumor of the kidney is 63% of cancers that affect the elderly and access to innovative therapies is through the identification of functional social needs. This neoplasm in Italy shows an increase due to diagnostic accuracy, with peaks between the sixth and seventh decade. in some cases it affects more members of a family whose tumor genesis is due to translocation between chromosomes (3.6.& 3.11) responsible for the onset hereditary. Perspective the development of new treatments is necessary appreciation TMN in younger patient’s geriatric with a forecast of even controversial outcomes. The pathological staging is an important prognostic factor4,5 as the histologic grade reflects the aggressiveness of the tumor that defines the evolution of the disease highlighting how the ploidy, p53, nuclear grading and morphology are related to the progression and therefore to the survival . the chance of recovery is related to the early stage of the disease and the degree of tumor spread .the surgical treatment it remains the only one for such localized forms for which it is necessary to conduct a more accurate screening in elderly patients.
Conclusion
Results of this study concludes that although from cases positive and encouraging results in terms of complete response, partial response and stable disease were obtained but they were not statistical significant. It was reported disappointing results (chemo, radio,) in our study have led to the use of modifiers biological response establishing itself as the treatment of choice (first results) in advanced kidney cancer, in combination with lIFN 2alfa. In the surgical treatment of the elderly patient itself is an important negative prognostic criteria. In elderly patients, therefore, need clear and appropriate specific guidelines that take into account for age, stage of disease, the typical old age illnesses that complicate significantly to prognosis. Additional molecular biology studies are useful for better understanding of the mechanisms that regulate the aging process and the onset of illness in old age.